Purpose: The objective of this study is the implementation of a kinetic model for 11C-desmethylloperamide (11C-dLop) and the determination of a typical parameter for P-glycoprotein (P-gp) functionality in mice. Since arterial blood sampling in mice is difficult, an alternative method to obtain the arterial plasma input curve used in the kinetic model is proposed.
Methods: Wild-type (WT) mice (pre-injected with saline or cyclosporine) and P-gp knock-out (KO) mice were injected with 20 MBq of 11C-dLop, and a dynamic μPET scan was initiated. Afterwards, 18.5 MBq of 18F-FDG was injected, and a static μPET scan was started. An arterial input and brain tissue curve was obtained by delineation of an ROI on the left heart ventricle and the brain, respectively based on the 18F-FDG scan.
Results: A comparison between the arterial input curves obtained by the alternative and the blood sampling method showed an acceptable agreement. The one-tissue compartment model gives the best results for the brain. In WT mice, the K1/k2 ratio was 0.4 ± 0.1, while in KO mice and cyclosporine-pretreated mice the ratio was much higher (2.0 ± 0.4 and 1.9 ± 0.2, respectively). K1 can be considered as a pseudo value K1, representing a combination of passive influx of 11C-desmethylloperamide and a rapid washout by P-glycoprotein, while k2 corresponds to slow passive efflux out of the brain.
Conclusions: An easy to implement kinetic modeling for imaging P-glycoprotein function is presented in mice without arterial blood sampling. The ratio of K1/k2 obtained from a one-tissue compartment model can be considered as a good value for P-glycoprotein functionality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250994 | PMC |
http://dx.doi.org/10.1186/2191-219X-1-12 | DOI Listing |
Crit Rev Oncol Hematol
January 2025
Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia; The Brain Cancer Group, Sydney, New South Wales, Australia; Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia.
Purpose: To summarise existing literature examining amino acid positron emission tomography (AA-PET) for radiotherapy target volume delineation in patients with gliomas.
Methods: Systematic search of MEDLINE and EMBASE databases.
Results: Twenty studies met inclusion criteria.
Eur J Nucl Med Mol Imaging
May 2024
Department of Nuclear Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
In Vivo
October 2021
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Background/aim: Auto-activation positron emission tomography (AAPET) is one of the most promising methods to verify beam range in carbon ion radiotherapy (C-ion RT). We aimed to confirm this for the first time in a clinical setting by performing AAPET in a patient with pancreatic cancer previously receiving coil embolisation of hepatic artery pseudoaneurysm.
Materials And Methods: A 70-year-old pancreatic head cancer patient was treated with C-ion RT on a clinical dose of 4.
Introduction: Standard neuroimaging protocols for brain tumors have well-known limitations. The clinical use of additional modalities including amino acid PET (aaPET) and advanced MRI (aMRI) techniques (including DWI, PWI, and MRS) is emerging in response to the need for more accurate detection of brain tumors. In this systematic review of the past 2 years of the literature, we discuss the most recent studies that directly compare or combine aaPET and aMRI for brain tumor imaging.
View Article and Find Full Text PDFQ J Nucl Med Mol Imaging
September 2018
Department of Neurology, University Hospital Cologne, Cologne, Germany.
Since its introduction in 2016, the revision of the World Health Organization (WHO) classification of central nervous system tumors has already changed the diagnostic and therapeutic approach in glial tumors. Blurring the lines between entities formerly labelled as "high-grade" or "low-grade", molecular markers define distinct biological subtypes with different clinical course. This new classification raises the demand for non-invasive imaging methods focusing on depicting metabolic processes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!